The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

LUND, SE / ACCESS Newswire / June 17, 2025 / Alligator Bioscience (STO:ATORX) - Lund, Sweden, 17 June 2025 - Alligator ...

Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization ...

Some blind vision loss cases have been linked to the use of weight-loss jabs, including Ozempic, so caution is recommended by ...

A comprehensive analysis conducted by public health experts at Novartis Romania reveals that Romanian patients may wait, on ...

LUND, SE / ACCESS Newswire / June 17, 2025 / Alligator Bioscience (STO:ATORX) - Lund, Sweden, 17 June 2025 - Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company deve ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in ...

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as ...

A research team at the University of Barcelona shows how allopurinol may prevent aortic aneurysm in Marfan syndrome, paving the way for new clinical trials.

BeOne Medicines (NASDAQ:ONC) gains FDA approval for a new tablet version of Brukinsa, simplifying dosage for patients.